Control of HIV infection by IFN-α: implications for latency and a cure

被引:0
作者
Nollaig M. Bourke
Silvia Napoletano
Ciaran Bannan
Suaad Ahmed
Colm Bergin
Áine McKnight
Nigel J. Stevenson
机构
[1] Trinity Translational Medicine Institute,School of Medicine
[2] Trinity College Dublin,Department of Medical Gerontology
[3] Mercer’s Institute for Successful Ageing,School of Biochemistry and Immunology
[4] St. James Hospital,Department of Genito Urinary Medicine and Infectious Diseases
[5] Trinity College Dublin,Blizard Institute School of Medicine and Dentistry
[6] St. James’s Hospital,undefined
[7] Queen Mary University of London,undefined
来源
Cellular and Molecular Life Sciences | 2018年 / 75卷
关键词
HIV; Interferon; Latency; Anti-viral; JAK/STAT; Cure;
D O I
暂无
中图分类号
学科分类号
摘要
Viral infections, including HIV, trigger the production of type I interferons (IFNs), which in turn, activate a signalling cascade that ultimately culminates with the expression of anti-viral proteins. Mounting evidence suggests that type I IFNs, in particular IFN-α, play a pivotal role in limiting acute HIV infection. Highly active anti-retroviral treatment reduces viral load and increases life expectancy in HIV positive patients; however, it fails to fully eliminate latent HIV reservoirs. To revisit HIV as a curable disease, this article reviews a body of literature that highlights type I IFNs as mediators in the control of HIV infection, with particular focus on the anti-HIV restriction factors induced and/or activated by IFN-α. In addition, we discuss the relevance of type I IFN treatment in the context of HIV latency reversal, novel therapeutic intervention strategies and the potential for full HIV clearance.
引用
收藏
页码:775 / 783
页数:8
相关论文
共 648 条
  • [81] Sun L(1989)Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome (AIDS) Ann Intern Med 111 280-undefined
  • [82] Chen ZJ(1983)Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma N Engl J Med 308 1071-undefined
  • [83] de Weerd NA(1998)Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi’s sarcoma associated with human immunodeficiency virus infection: a Canadian HIV Clinical Trials Network study J Clin Oncol 16 1736-undefined
  • [84] Vivian JP(2010)Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial J Infect Dis 201 1686-undefined
  • [85] Nguyen TK(2001)Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study AIDS 15 1435-undefined
  • [86] Mangan NE(2016)Interferons and HIV infection: the good, the bad, and the ugly Pathog Immun 1 107-undefined
  • [87] Gould JA(2004)New approaches to the treatment of AIDS with special reference to overcoming interferon resistance J Med 35 201-undefined
  • [88] Braniff SJ(1997)Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy Science 278 1295-undefined
  • [89] Zaker-Tabrizi L(1997)Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy Proc Natl Acad Sci USA 94 13193-undefined
  • [90] Fung KY(2014)Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1 Proc Natl Acad Sci USA 111 13475-undefined